Editas Medicine Inc.

58.71-3.36-5.41%Vol 1.16M1Y Perf 103.85%
Sep 24th, 2021 16:00 DELAYED
BID58.60 ASK58.78
Open61.31 Previous Close62.07
Pre-Market- After-Market58.86
 - -  0.15 0.26%
Target Price
58.20 
Analyst Rating
Moderate Buy 2.29
Potential %
-0.87 
Finscreener Ranking
★★     46.09
Insiders Trans % 3/6/12 mo.
-100/-100/-79 
Value Ranking
★★★     50.73
Insiders Value % 3/6/12 mo.
-100/-100/-52 
Growth Ranking
★★     46.11
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-51 
Income Ranking
 —    -
Price Range Ratio 52W %
43.46 
Earnings Rating
Strong Buy
Market Cap4.01B 
Earnings Date
4th Nov 2021
Alpha0.02 Standard Deviation0.25
Beta1.94 

Today's Price Range

58.6961.54

52W Range

27.0199.95

5 Year PE Ratio Range

-8.20-10.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-7.10%
1 Month
-10.49%
3 Months
40.19%
6 Months
39.19%
1 Year
103.85%
3 Years
80.26%
5 Years
306.02%
10 Years
-

TickerPriceChg.Chg.%
EDIT58.71-3.3600-5.41
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
9.30
9.30
0.03
0.05
219.50
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-208.50
-202.80
-721.10
-87.89
RevenueValueIndustryS&P 500US Markets
81.14M
1.19
48.79
67.61
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.85-0.814.71
Q01 2021-0.76-0.86-13.16
Q04 2020-0.82-1.00-21.95
Q03 2020-0.660.12118.18
Q02 2020-0.80-0.4346.25
Q01 2020-0.78-0.6911.54
Q04 20190.35-0.74-311.43
Q03 2019-0.73-0.669.59
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.867.53Positive
12/2021 QR-1.011.94Positive
12/2021 FY-3.592.18Positive
12/2022 FY-3.623.98Positive
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.86
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume1.16M
Shares Outstanding68.26M
Shares Float58.07M
Trades Count15.36K
Dollar Volume168.10M
Avg. Volume1.97M
Avg. Weekly Volume1.06M
Avg. Monthly Volume1.43M
Avg. Quarterly Volume2.01M

Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 58.71 per share at the end of the most recent trading day (a -5.41% change compared to the prior day closing price) with a volume of 1.17M shares and market capitalization of 4.01B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.

The one-year performance of Editas Medicine Inc. stock is 103.85%, while year-to-date (YTD) performance is -16.26%. EDIT stock has a five-year performance of 306.02%. Its 52-week range is between 27.01 and 99.95, which gives EDIT stock a 52-week price range ratio of 43.46%

Editas Medicine Inc. currently has a PE ratio of -24.30, a price-to-book (PB) ratio of 7.03, a price-to-sale (PS) ratio of 48.96, a price to cashflow ratio of 616.40, a PEG ratio of 2.32, a ROA of -23.03%, a ROC of -30.46% and a ROE of -31.34%. The company’s profit margin is -87.89%, its EBITDA margin is -202.80%, and its revenue ttm is $81.14 Million , which makes it $1.19 revenue per share.

Of the last four earnings reports from Editas Medicine Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. Editas Medicine Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Editas Medicine Inc. is Moderate Buy (2.29), with a target price of $58.2, which is -0.87% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Editas Medicine Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.01, ATR14 : 3.98, CCI20 : -87.50, Chaikin Money Flow : -0.12, MACD : 0.19, Money Flow Index : 38.53, ROC : -8.72, RSI : 46.36, STOCH (14,3) : 9.57, STOCH RSI : 0.16, UO : 42.54, Williams %R : -90.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Charles Albright (Option Excercise at a value of $1 320 800), Charles Albright (Sold 86 000 shares of value $3 953 453 ), Cynthia Collins (Sold 2 524 shares of value $168 225 ), James C. Mullen (Buy at a value of $1 156 800), Jessica Hopfield (Buy at a value of $263 970), Michelle Robertson (Option Excercise at a value of $153 250), Michelle Robertson (Sold 6 568 shares of value $397 727 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (28.57 %)
1 (16.67 %)
2 (28.57 %)
Moderate Buy
1 (14.29 %)
1 (16.67 %)
1 (14.29 %)
Hold
4 (57.14 %)
4 (66.67 %)
4 (57.14 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.29
Moderate Buy
2.50
Moderate Buy
2.29

Editas Medicine Inc.

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.

CEO: Cynthia Collins

Telephone: +1 617 401-9000

Address: 11 Hurley Street, Cambridge 02141, MA, US

Number of employees: 235

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

59%41%

Bearish Bullish

60%40%

InvestorsHub News for EDIT

News

Stocktwits